Chao-Xia Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chao-Xia Liu has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Ke-Jia Zhang
Department of Pathophysiology
1 shared publication - Lei Ding
Department of Pathophysiology, Xuzhou Medical University, Xuzhou 221004, China
1 shared publication - Li Li
Department of Pathophysiology, School of Basic Medical Sciences, Xuzhou Medical University, Xuzhou, China
1 shared publication - Ming Xu
Department of Pathophysiology
1 shared publication - Qi Wu
Department of Physiology, Xuzhou Medical University, Xuzhou, 221009, China
1 shared publication - Shi-Min Jiang
Department of Pathophysiology
1 shared publication
Latest Publications
- Open Access
- 1 January 2021
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2021 (1)
Pyroptosis: A New Frontier in Kidney Diseases
Pyroptosis is a pattern of programmed cell death that significantly differs from apoptosis and autophagy in terms of cell morphology and function. The process of pyroptosis is characterized predominantly by the formation of gasdermin protein family‐mediated membrane perforation, cell collapse, and the release of inflammatory factors, including IL‐1β and IL‐18. In recent years, with the rise of pyroptosis research, scholars have devoted time to study the mechanism of pyroptosis in kidney‐related diseases. Pyroptosis is probably involved in kidney diseases through two pathways: the caspase‐1‐mediated canonical pathway and the caspase‐4/5/11‐mediated noncanonical pathway. In addition, some scholars have identified targets for the treatment of kidney‐related diseases from the viewpoint of pyroptosis and developed corresponding medicines, which may become a recommendation for prognosis, targeted treatment, and clinical diagnosis of kidney diseases. This paper focuses on the up‐to‐date advances in the field of pyroptosis, especially on the key pathogenic role of pyroptosis in the development and progression of kidney diseases. It presents a more in‐depth understanding of the pathogenesis of kidney diseases and introduces novel therapeutic targets for the prevention and clinical treatment of kidney diseases.
- 1 January 2021
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2021 (1)
Open AccessPyroptosis: A New Frontier in Kidney Diseases
Pyroptosis is a pattern of programmed cell death that significantly differs from apoptosis and autophagy in terms of cell morphology and function. The process of pyroptosis is characterized predominantly by the formation of gasdermin protein family‐mediated membrane perforation, cell collapse, and the release of inflammatory factors, including IL‐1β and IL‐18. In recent years, with the rise of pyroptosis research, scholars have devoted time to study the mechanism of pyroptosis in kidney‐related diseases. Pyroptosis is probably involved in kidney diseases through two pathways: the caspase‐1‐mediated canonical pathway and the caspase‐4/5/11‐mediated noncanonical pathway. In addition, some scholars have identified targets for the treatment of kidney‐related diseases from the viewpoint of pyroptosis and developed corresponding medicines, which may become a recommendation for prognosis, targeted treatment, and clinical diagnosis of kidney diseases. This paper focuses on the up‐to‐date advances in the field of pyroptosis, especially on the key pathogenic role of pyroptosis in the development and progression of kidney diseases. It presents a more in‐depth understanding of the pathogenesis of kidney diseases and introduces novel therapeutic targets for the prevention and clinical treatment of kidney diseases.